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Summary 
Human articular cartilage cells were cultured in 1.5% agarose in Dulbecco's modified Eagle's medium (DMEM) with 10% 
fetal calf serum or in serum-free DMEM with 0.15% bovine serum albumin. ~sS-aggrecan synthesis in serum-free DMEM 
was between 20% and 30% of the value observed in DMEM supplemented with 10% fetal calf serum. The extent o which 
different growth or differentiation factors were able to restore 3~S incorporation in aggrecan in serum-free DMEM was 
determined: human serum transferrin had no effect on aggrecan synthesis levels; bovine pancreas insulin, insulin-like 
growth factor (IGF)-I and IGF-2 restored 35S-aggrecan synthesis to 35-50% of the control levels. The effects were 
dose-dependent, to level off at 100 ng/ml for the three factors. No cumulative or synergistic activities were observed when 
these factors were combined. Transforming growth factor (TGF)-fl, at concentrations ranging from 10-50 ng/ml stimulated 
aggrecan synthesis to approximately 50% of the control values in the chondrocytes obtained from two out of four donors, 
while the cells of the other two maintained within the range of the control levels. In the presence of insulin (100 ng/ml) 
10 ng/ml of TGF-fl stimulated aggrecan synthesis to more than 90% of  the control evel in the chondrocytes ofall donors. 
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Introduction 
IN MOST IN VITRO cu l ture  systems, fetal  ca l f  serum 
(FCS) is used as a source of growth and 
di f ferent iat ion factors. However, FCS is a poor ly 
defined supp lement  in that  it conta ins an unknown 
amount  of components  at concentrat ions  that  may 
vary  widely from batch to batch. FCS conta ins some 
of these factors  at doses that  produce a max imal  
biologic effect. In studies on the inf luences exerted 
by cytok ines or growth and di f ferent iat ion factors  
on metabol ic  act iv it ies of cel ls--e.g,  on the synthesis  
and turnover  of aggrecans  by chondrocytes  
in vitro--one cannot  be cer ta in  how far effects, i f  
any, are str ict ly  re lated to the biological  act ions of 
the tested factors. These possible inter ferences can 
be avoided if complete ly  defined serum-free cu l ture 
media  are used. Strategies  for the development  of 
serum-free nut r ient  media  have been reviewed [1]. 
Insul in- l ike growth factor  ( IGF)-I  and IGF-2 are 
anabol ic  and mitogenic  pept ides of 7.5 kDa known 
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to s t imulate  the growth of a var ie ty  of somat ic  cells 
in culture.  These peptides, which are main ly  
produced in the liver, c i rcu late  in assoc iat ion  wi th  
specific car r ie r  or b ind ing prote ins [2] and share  
many bio logical  act iv i t ies with insul in  [3, 4]. A 
serum-free nut r ient  med ium conta in ing  IGF-1 
and IGF-2 amongst  other  factors  suppor t  DNA 
synthesis  in monolayer  cu l tured rabbit  men isca l  
f ibrochondrocytes at a level equivalent  o 10% FCS 
[5]. Rabbi t  a r t i cu la r  chondrocytes  cu l tu red  in 
monolayers  in the presence of IGF-1 s igni f icant ly  
increase the synthes is  of both  col lagen and 
glycosaminoglycans [6]. F ibrob last  cell l ines have 
been repor ted  to sus ta in  the i r  DNA synthes is  wi th  
insul in and t ransfer r in  as hormone supp lements  in 
serum-free condit ions [7]. Well-defined media,  
supi~lemented with IGF-1 and IGF-2 or pharmaco-  
logical  doses of insul in,  are able to ma inta in  an 
opt imal  aggrecan b iosynthes is  and catabo l i sm in 
short-  and long-term bovine ar t i cu la r  car t i lage 
explants  [8, 9]. In h igh-densi ty  monolayer  cu l ture  of 
chondrocytes  from mammals ,  IGF-1 appears  to act  
as a d i f ferent iat ing factor  by st imulat ing prote in  
synthesis  and type I I  col lage mRNA,  but p revent ing  
expression of  the type I col lagen gene [10]. IGF-2 
appears  to be the most  abundant  growth factor  in 
human bone and it has been shown to be s imi lar  to 
skeletal  growth factor  [11]. S t imulatory  act ion of 
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IGF-1 on human bone explants in serum-free 
conditions have been recently described [12]. 
Transforming rowth factor-fl (TGF-fl), a 25 kDa 
homodimeric polypeptide, abounds in cartilage and 
bone [13]. TGF-fl induces chondrogenic differen- 
tiation (synthesis of proteoglycan and of type II 
collagen) in mesenchymal cells cultured in agarose 
[14]. TGF-fl regulates aggrecan metabolism in 
bovine articular cartilage explants [15] and 
promotes fibronectin and aggrecan synthesis in 
serum-free medium supplemented with calcium and 
insulin [16]. In studies performed with rabbit 
articular chondrocytes in monolayer culture, 
TGF-fl has been shown not to prevent dedifferenti- 
ation in low-serum incubation media [17]. Never- 
theless, production of aggrecans and of type II and 
XI collagen has been observed in serum-free 
conditions [18]. TGF-fl appears to be a potent 
inhibitor of the interleukin-1 (IL-1)-induced egra- 
dation of the cartilage matrix [18-20]. TGF-fi, alone 
or in combination with basic fibroblast growth 
factor, inhibits autocrine IGF-1 production rabbit 
articular chondrocytes, but stimulates IGF-1 pro- 
duction in murine osteoblast-like cells [21]. 
Since TGF-fl, insulin and IGFs may directly or 
indirectly affect connective tissue cells, we studied 
the effects of these growth and differentiation 
factors on aggrecan synthesis rates of human 
articular chondrocytes in agarose in serum-free 
conditions. 
The agarose system was used since isolated 
chondrocytes in this artificial matrix were shown to 
maintain their differentiated function and were 
easily accessible for exogenous factors. 
Mater ia ls  and methods  
HUMAN ARTICULAR CHONDROCYTES 
Human articular chondrocytes were isolated as 
described elsewhere [22, 23], with a few modifi- 
cations. Articular cartilage was obtained at autopsy 
Table I 
List of human donors 
Age 
No. Sex (years) Cause of death 
1 M 2 Open heart surgery 
2 M 20 Car crash 
3 M 41 Lung cancer 
4 M 42 Bleeding due to thrombopenia 
5 F 44 Traffic accident 
6 M 57 Gut cancer 
7 M 59 Cerebrovascular accident 
8 M 63 Lung cancer 
9 M 64 Thrombosis abdominal orta 
from nine donors (Table I) within 24 h post mortem. 
All donors had died after a short illness. None had 
been receiving corticosteroids or cytostatic drugs. 
Specific characteristics of the donors are given 
within the discussion of each experiment. Visually 
intact cartilage was sampled from the femur 
condyles, diced in small fragments and digested in 
a spinner bottle. All enzymatic solutions were made 
in Dulbecco's modified Eagle's medium (DMEM; 
Gibco) with antibiotics and antimycotics (penicillin 
10 u/ml; streptomycin 10 ttg/ml; fungizone 0.025 pg/ 
ml; Gibco), 0.002 M/ml L-glutamine and 10% of FCS 
when specified. 
Articular cartilage was treated: with 0.25% of 
sheep testes hyaluronidase (Sigma) in DMEM for 
120 rain at 37°C. The hyaluronidase solution was 
then replaced by 0.25% of Pronase (Streptomyces 
griseus Pronase E; Sigma) in DMEM for 90 min at 
37°C. The cartilage was then washed twice with 
DMEM containing 10% of FCS and stored 
overnight in the same incubation medium at 37°C. 
The next day the tissue was solubilized following 
a 3-6h 0.25% collagenase (Clostridium his- 
tolyticum; Sigma) treatment at 37°C. Cells were 
then centrifuged for 10 rain at 800 g, washed three 
times with DMEM with FCS, tested for viability 
(Trypan Blue exclusion test) and counted. Rou- 
tinely, approximately 30-50 × 106 viable cells were 
isolated from the several grams of cartilage that 
had been removed from one knee joint. Usually, 
more than 95% of the cells were viable after 
isolation. 
CHONDROCYTES IN AGAROSE CULTURE 
Chondrocytes were cultured in gelified agarose 
as previously described [24] with some modifi- 
cations [25, 26]. The cultures were set up in 3.8 ml 
cryotubes (NUNC). The agarose used was ultralow 
gelling temperature agarose (Type IX, gelling at 
less than 15°C and remelting at less than 50°C; 
Sigma) for the simple reason that this agarose is 
easy to work with at room temperature. Three per 
cent agarose in distilled water was autoclaved 
twice for 15 rain and prior to use stored at 4-8°C. 
The cryotubes were coated with 100 gl of this 3% 
agarose and the coating was then allowed to gelify 
at 4-8°C. 
Chondrocyte suspension cultures were estab- 
lished in 1.5% agarose concentrations. Three per 
cent (double concentrated) agarose gel was melted 
before use, kept at 37°C and mixed with an equal 
volume of 2 × DMEM (for 50 ml of 2 × DMEM: 1.337 g 
lyophylized DMEM, 0.37g NaHCO3 and 10mg 
ascorbate in 40 ml distilled water and 10 ml FCS; to 
sterilize through a 0.22/~m pore membrane filter) 
Osteoarthrit is and Cartilage Vol. 3 No. 4 251 
with 20% FCS to give the desired concentration 
of agarose in DoMEM with 10% FCS. Thereafter, 
0.1 vol. of the chondrocyte suspension wasadded to 
the soluble agarose in DMEM. The final cell density 
was approx. 1.5×106 chondrocytes per culture. 
Coated cryotubes were filled with 300 #1 of agarose, 
and kept at 4-8°C for 15 min to allow the agarose to 
gelify. Three millilitres of the appropriate incu- 
bation medium were then added and the cultures 
were placed in a moist culture chamber (Modular 
incubation chamber, Flow Laboratories) at 37°C 
under 5% CO2/95% air for 2 weeks. Nutrient 
medium (plus 50 #g/ml of freshly dissolved ascor- 
bate) was replaced thrice weekly. 
SYNTHESIS OF AGGRECANS 
Synthesis of aggrecans was investigated using 
Na285SO4 as a radioactive precursor. Some 10 pCi/ml 
of the label were included in the incubation medium 
during 48 h. Newly synthesized 35S-aggrecans partly 
accumulated in the artificial intercellular agarose 
matrix. Another part of these 3~S macromolecules 
escaped to the incubation medium. The agarose was 
mechanically disrupted and digested in the culture 
dish using 3.0 ml of an 50 u/ml agarase solution 
(agarose 3-glycanohydrolase from Pseudomonas 
atlantica; Sigma) in 0.067 M phosphate pH 6.0 in the 
presence of proteinase inhibitors (0.1 M e-amino-n- 
caproic acid, 0.01 M EDTA, 0.005 M benzamidine- 
chloride and 0.01 M methylsulphonyl-fluoride [27] at 
40°C overnight. Electron microscopy of the 
aggrecan aggregates and Sepharose CL-2B gel 
permeation chromatography of the proteoglycans 
allowed to study the matrix proteoglycans, which 
were solubilized in the presence of protease 
inhibitors. The agarase digest of the agarose gel 
contained native aggrecan aggregates, monomeric 
aggrecan and other proteoglycan subtypes [25, 26]. 
The resultant suspension was centrifuged. The 
supernatant and the incubation medium were 
pooled for further chromatography. 
ANALYSIS OF 35S-AGGRECAN SUBPOPULATIONS 
After centrifugation, aliquots of pools of com- 
bined media and agarose digests were desalted 
through Sephadex G25 (Pharmacia) chromato- 
graphy gels in 0.067 M phosphate (K2HPO4/ 
Na~HPO4), pH 6.8, containing 0.01 M Na2SO4 in 
order to separate 3~S-labelled aggrecans from free 
3~sulphate. The eluted fractions were counted for 
radioactivity. The radioactivity under the curves is 
related to the total incorporation of ~Ssulphate in 
~SS-aggrecans by the respective cultures. 
Considering the amount of pooled culture 
medium that ultimately was analyzed after chroma- 
tography, the specific activity of the incubation 
medium (pCi SO4/#M cold SO4), the decay of 
3~sulfate, the labelling period in hours and the 
numbers of cells per culture, we were able to express 
the incorporation of SO4 as picogram of SO4 
incorporated per 1 × 106 chondrocytes per hour. 
Fractions containing the 35S-labelled macromol- 
ecules were pooled and used for further analysis of 
their molecular size by gel permeation chromato- 
graphy on Sepharose CL-2B (Pharmacia) in 0.067 M 
phosphate (K2HPO4/Na2HPO4), pH 6.8, with 0.01 M 
Na2SO4. 
CL-2B Sepharose gel chromatography fraction- 
ates polysaccharide macromolecules ranging from 
1 x 107-1 × 105 kDa. Aggrecan aggregates are ex- 
pected to be excluded from this gel and typically 
will appear in the void volume of an elution, 
whereas different size monomeric aggrecans will be 
retained and elute in a retarded position. A third 
peak may appear, containing some low molecular 
weight material, the exact nature of which has not 
been investigated (aggrecan breakdown products, 
low molecular size proteoglycans). The radioac- 
tivity under the curves allowed to calculate the 
proportions of the different 3~S macromolecules a  
well as the absolute amounts of 35S activity 
incorporated in the respective proteoglycan popu- 
lations. 
It is not likely that aggrecan aggregate formation 
could have resulted from mixing monomeric 
aggrecan in the media with an excess of free 
hyaluronan in the matrix digests. Approximately 
50% of the newly synthesized aggrecans remained in 
the agarose gel and in the surroundings of the cells 
[25]. These unbound aggrecans clearly outnumbered 
the hyaluronan molecules in the extracellular 
matrix. Aggrecan aggregates isolated from the 
agarose gel showed hyaluronan chains that were 
completely loaded with aggrecan. No free or 
partially loaded hyaluronan molecules were seen 
[26]. 
CH2kRACTERIZATION OF THE CONTENTS OF THE THREE 
MAIN FRACTIONS ON SEPHAROSE CL-2B 
35S-labelled macromolecules obtained after G25- 
Sephadex chromatography ave been digested with 
hyaluronan-specific leech hyaluronidase (Sigma), 
200 u/ml in 0.067 M phosphate pH 5.3, at 37°C, 24 h, 
with trypsin (0:25 mg/ml in 0.067 M phosphate, pH 
7.0, 1 h at 37°C) and with testicular hyaluronidase 
[sheep testes (Sigma) 1500 NFU/ml in 0.067M 
phosphate pH 7.0, 12 h at 37°C] before elution on 
Sepharose CL-2B in order to characterize the 
contents of the three main fractions. 
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EFFECTS OF GROWTH AND DIFFERENTIAT ION FACTORS 
All experiments were done three- or four-fbld. 
Basal metabolic activity was assessed in cultures 
grown in DMEM with 10% FCS. Maximal 
depression was obtained in cultures maintained in 
serum-free DMEM with 0.5% of bovine serum 
albumin (BSA). Metabolic activity was assayed after 
2 weeks of culture under the different regimens. 
Depression and recovery of ~5S incorporation in 
proteoglycan with the different factors in serum- 
free DMEM were expressed as percentage of basal 
metabolic activity. 
Human recombinant insulin-like growth factor 
(hr-IGF)-I and IGF-2 (greater than 95% pure; 
Boehringer Mannheim), were separately tested at 0, 
1, 10, 50 and 100 ng/ml DMEM with 0.5% BSA. 
Insulin-transferrin sodium-selenite complex 
(ITSS), human serum transferrin and bovine 
pancreas insulin were purchased from Boehringer 
Mannheim. Insulin and transferrin were firstly 
separately tested at concentrations of 0, 1, 10 and 
100ng/ml serum-free DMEM (with 0.5% BSA). 
Transferrin at the same concentration was tested in 
serum-free DMEM in the presence o f  either 
100 ng/ml of insulin or 100 ng/ml of IGF-2. The 
effects of ITSS complex were assayed at 5 pg/ml 
concentrations. 
Human recombinant transforming growth factor- 
fl (hr-TGF-fl) (purified from platelets and purchased 
from Calbiochem) was tested at concentrations 
ranging from 1-50 ng/ml as a single factor and in the 
presence of 100 ng insulin per ml of serum-free 
DMEM. 
STATISTICS 
Each experiment was done three- or four-fold. 
Mean values, the standard eviation (S.D.) and the 
coefficient of variation (CV = 1 S.D. × 100/mean) were 
calculated. 
Resu l ts  
ANALYSIS OF 35S-AGGRECAN SUBPOPULAT IONS 
A typical chromatography curve of 85S-proteogly- 
cans on a Sepharose CL-2B gel is given in Fig.1. 
When pooled '~sS-labelled macromolecules (G25 
sephadex gels) were treated with leech 
hyaluronidase and eluted on CL-2B Sepharose, the 
~sS-labelled material from the first peak entirely 
moved to a retarded position. This first peak mainly 
contained 35S-labelled, high molecular weight leech 
hyaluronidase-sensitive aggrecan aggregates, which 
were degraded to monomeric aggrecan. The curve of 
a hyaluronidase digest shows a rather asymmetrical 
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FIG. 1. Elution profiles of 35S-labelled proteoglycans (PG). 
(a) native PG: K~v aggrecan aggregates = 0.0 (V0); K~v low 
molecular weight PG =0.71. (b) 1, Leech hyaluronidase 
digested PG: K~v monomeric aggrecans = 0.12. 2, Trypsin 
digested PG: Kov major ~'~S-peptidoglycans=0.82. 3, 
Testicular hyaluronidase digested PG. 
peak with a relatively low proportion of ~SS-activity 
eluted with a Kay of 0.12 or higher. This may indicate 
some incomplete digestion of the hyaluronan by the 
leech hyaluronidase or the presence of an immature 
aggrecan population of a larger hydrodynamic size 
[25]. Digestion of the 35S-labelled macromolecules 
with trypsin or with testicular hyaluronidase moved 
most of the radioactivity to the tailing fractions. 
EFFECTS ON AGGRECAN SYNTHESIS 
Insulin and the IGF were tested as single factors. 
SOn-incorporation by chondrocytes cultured in 
DMEM with 10% FCS was compared with 
SO4-incorporation of the same cells in DMEM 
with 0.5% BSA. Effects resulting from the addition 
of different concentrations of these factors to 
serum-free DMEM are given in Table II. The three 
growth factors increased 3~S incorporation in 
aggrecan in a dose-dependent way. However, whilst 
35S incorporation in serum-free conditions fell to 
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Table II 
Effects of human recombinant insulin-like growth factor (hr-IGF)-i and -2, and of 
bovine pancreas insulin on 3~S incorporation in aggrecan by chondrocytes in
suspension culture 
Medium 
factor Mean 
S04 incorporation i  aggrecans 
pg/1 × 106 cells/h Aggrecan aggregates (%) 
CV Control (%) Mean CV Control (%) 
Donor 9 
10% FCS 2350 (9.3) 100 40.2 (4.1) 100 
0.5% BSA 472 (6.5) 20 16.6 (2.2) 41 
hr-IGF-1 
i ng/ml 435 (8.3) 18 17.8 (10.8) 44 
50 ng/ml 775 (0.1) 33 16.4 (0.4) 41 
100 ng/ml 931 (5.2) 39 23.2 (2.4) 58 
Donor  6 
10% FCS 2341 (1.7) I00 38.3 (5.3) I00 
0.5% BSA 536 (11.9) 23 20.5 (11.3) 54 
hr-IGF-2 
1 ng/ml 486 (10.5) 21 19.5 (8.1) 51 
10 ng/ml 641 (5.9) 27 20.4 (6.8) 53 
50 ng/ml 840 (4.2) 36 24.0 (2.9) 63 
100 ng/ml 985 (4.1) 42 30.5 (5.3) 80 
Donor 6 
10% FCS 2341 (1.7) 100 38.3 (5.3) 100 
0.5% BSA 536 (11.9) 23 20.5 (11.3) 54 
Bovine pancreas insulin 
i ng/ml 686 (9.5) 29 18.7 (7.2) 49 
10 ng]ml 852 (4.9) 36 21.9 (2.7) 57 
100 ng/ml 1249 (3.3) 53 27.5 (10.4) 72 
FCS, fetal calf serum; BSA, bovine serum albumin. 
Percentage of the control situation = 10% FCS. 
Donor numbers refer to Table I. 
approximately 20% of the control  (FCS) values, 
IGF-1, IGF-2 and insul in restored 35S incorporat ion 
to 39, 42 and 53% of the control  values, respectively. 
Doses above 100 ng/ml, the opt imal concentrat ion of
these factors, did not  result  in further  increase of 
SO4 incorporat ion.  The effects of the optimal 
concentrat ions  of IGF-1, IGF-2 and of insul in were 
tested in another  series of donors (Tables III, IV & 
V). Again, ~S incorporat ion  was only part ly restored 
and amounted to approximately 50, 40 and 52% of 
the control  values for IGF-1, IGF-2 and insulin, 
respectively. 
The same results were obtained when the 
cells were cul tured in the presence of hr-TGF-fl 
(Table VI). TGF-fl, at concentrat ions rang ing  from 
10 to 50ng/ml,  st imulated aggrecan synthesis  to 
approximately 50-60% of the control  values in the 
chondrocytes obtained from two out of four donors, 
Table III 
Effects of 100 ng/ml human recombinant insulin-like growth factor (hr-IGF)-I on 3~S incorporation in 
aggrecan by chondrocytes in suspension culture 
10% FCS 0.5% BSA hr-IGF-1 
Donor Mean CV Control (%) Mean CV Control (%) Mean CV Control (%) 
SO4 incorporation i aggrecans (pg/1 × 106 cells/h) 
1 9679 16.5 100 2188 7.1 23 6357 19.0 66 
9 2350 9.3 100 472 6.5 20 931 5.2 39 
2 6520 11.0 100 1489 18.0 23 2864 4.0 44 
Mean 100 20.0 49.7 
_+ 1 S.D. 0 6.1 21.9 
35S in aggrecan aggregates (%) 
9 36.4 2.3 I00 17.5 9.0 48 20.6 8.6 57 
FCS, fetal calf serum; BSA, bovine serum albumin. 
Donor numbers refer to Table I. 
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Table IV 
Effects of 100 ng/ml human recombinant insulin-like growth factor (hr-IGF)-2 on 35S incorporation in 
aggrecan by chondrocytes in suspension culture 
10% FCS 0.5% BSA hr-IGF-2 
Donor Mean CV Control (%) Mean CV Control (%) Mean CV Control (%) 
SO4incorporation i  aggrecans (pg]l × 108 cells/h) 
6 2341 1.7 100 536 11.9 23 985 4.1 42 
2 6520 11.0 100 1489 18.0 23 2863 1.7 44 
~5S in aggrecan aggregates (%) 
6 38.3 5.3 100 20.5 11.3 54 30.5 5.3 80 
2 36.4 2.3 100 17.5 9.0 48 20.1 7.4 55 
FCS, fetal calf serum; BSA, bovine serum albumin. 
Percentage of control situation = 10% FCS. 
Donor numbers refer to Table 1. 
while the cells of the other two remained within the 
range of the control  levels. 
Insul in at 100 ng/ml, in combinat ion with hr- 
TGF-fi at 10 ng]ml st imulated aggrecan synthesis to 
more than 90% of the control  level in the 
chondrocytes of five donors tested (Table VI). Both 
cytokines howed additive effects. This was not the 
case when insul in and IGF-1 were combined 
(Table VII). 
Human serum t rans fer r in - -a lone  or in combi- 
nat ion with insu l in - -had  no effects on aggrecan 
synthesis in this in vitro model (Table IX). Effects of 
these growth factors on 35S incorporat ion in 
proteoglycan- -as  a percentage of cont ro l - -a re  
given in Fig, 2. 
EFFECTS ON PROTEOGLYCAN SUBTYPES 
When FCS was replaced by BSA, proport ions 
of aggrecan aggregates decreased dramatically. 
Insul in, IGF-1 and IGF-2 sl ightly increased the 
relative amount  of aggrecan aggregates synthesized 
by some of the chondrocyte batches (Tables II-V, VII, 
VIII). The combined effects of insul in and TGF-fl on 
the aggrecan subtypes was studied in one donor. In 
this case, the t reatment  did not improve the 
proport ions of aggrecan aggregates (Table VIII). 
Discuss ion  
The presence of FCS in the incubat ion media 
of cell cultures interferes with the interpretat ion 
Table V 
Effects of 100 ng/ml bovine pancreas insulin on ~5S incorporation in aggrecan by chondrocytes in suspension 
culture 
10% FCS 0.5% BSA Bovine pancreas insulin 
Donor Mean CV Control (%) Mean CV Control (%) Mean CV Control(%) 
SO4 incorporation i aggrecans (pg/1 x 106 cells/h) 
6 2341 1.7 100 536 11.9 23 1249 3.3 53 
9 2350 9.0 100 776 3.0 33 1293 9.0 55 
8 1302 10.0 100 504 10.0 39 .780 4.0 60 
3 2778 5.0 100 488 10.0 18 1532 16.0 55 
1 9679 17.0 100 2188 7.0 23 5766 16.0 60 
9 2350 9.0 100 329 3.0 14 705 3.0 30 
2 6520 11.0 100 1489 18.0 23 3344 9.9 51 
Mean 100 24.7 52.0 
± I S.D. 0 8.6 10.3 
s~S in aggrecan aggregates (%) 
6 38.3 5.3 100 20.5 11.3 54 27.5 10.4 72 
3 27.6 4.8 100 19.2 9.7 70 18.9 7.4 68 
2 36.4 2.3 100 17.5 9.0 48  21.2 5.1 58 
Mean 100 57.3 66.0 
± 1 S.D. 0 8.4 5.3 
FCS, fetal calf serum; BSA, bovine serum albumin. 
Percentage of control situation = 10% FCS. 
Donor numbers refer to Table I. 
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Table VI 
Effects of human r~combinant transforming rowth factor (TGF)-fl as a single mediator or in combination with bovine 
pancreas insulin on ~5S incorporation in aggrecan by chondrocytes in suspension culture (pg/1 × 106 cells/h) 
Donor 
FCS BSA 
Mean CV Mean CV Control (%) 
TGFfl 
1 ng]ml 10 ng/ml 50 ng/ml 
Mean CV Mean CV Control (%) Mean CV Control (%) 
9 2350 9 776 3 33 870 1 1222 3 52 
8 1302 10 504 10 38 . . . . .  
3 2778 5 488 10 18 . . . . .  
1 9679 17 2188 7 23 - -  - -  2840 5 29 
7 3771 14 1075 16 29 1274 6 865 9 23 
Mean 28.2 
± 1 S.D. 7.9 
m _ _  m 
_ _  _ _  m 
1754 10 63 
1103 25 29 
FCS BSA Insulin 
Donor Mean CV Mean CV Control (%) Mean CV 
Insulin + TGFfl 
I ng/ml 10 ng/ml 50 ng/ml 
Mean CV Mean CV Control(%) Mean CV Control(%) 
9 2350 9 776 3 33 1293 9 1857 4 2280 4 97 
8 1302 10 504 10 38 780 4 997 8 1241 4 95 
3 2778 5 488 10 18 1532 16 2002 8 2531 5 91 
1 9679 17 2188 7 23 5766 16 - -  - -  8681 9 90 
5 4697 23 1393 16 30 . . . .  4363 11 93 
Mean 28.4 93.2 
+ 1 S.D. 8.0 2.9 
_ _  n 
2553 8 92 
FCS, fetal calf serum; BSA, bovine serum albumin. 
The insulin concentration was 100 ng/ml. 
Donor numbers refer to Table I. 
of the results of metabol ic studies with var ious 
biologic mediators in in vitro systems. In order to 
obtain a well-defined incubat ion medium for human 
chondrocyte suspension cultures, FCS was replaced 
by one or more growth or dif ferentiat ion fact0rs. 
This would enable investigators to fully control  the  
in vitro environment and to standardize the culture 
system. We studied to what  extent human 
recombinant  IGF-1 and IGF-2, bovine pancreas 
insulin, human serum transferr in  and/or  human 
TGF-fl were able to restore 35S incorporat ion in 
proteoglycan i serum-free DMEM.  
'De novo' synthesis of proteoglycans was assayed 
as 35S activity in macromolecules lut ing in the void 
volume of a G25-Sephadex gel f i ltration experiment. 
3~S-proteoglycan breakdown products also were 
considered to be newly synthesized macromol-  
ecules, which were subsequent ly degraded but still 
eluted with other  35S-macromolecules on G25-Sepha- 
dex gel chromatography. A shift of 35S-activity on the 
CL-2B chromatograms from the left ( intact aggrecan 
aggregates) to the r ight  (monomeric aggrecan) 
fract ions indicates a fai lure (catabolism?) in the 
assembly of aggrecans in larger aggregates. In most 
in vitro condit ions tested so far, the major i ty  of 3~SO4 
used by phenotypica l ly  stable cart i lage cells is 
incorporated in aggrecan. Variat ions in low 
hydrodynamic size proteoglycans such as decorin, 
Table VII 
Effects of bovine pancreas insulin combined with human recombinant insulin-like growth factor 
(hr-IGF)-I or with transferrin, on ~5S incorporation i~ aggrecan by chondrocytes in suspension culture 
pg/106 cells/h Aggrecan aggregates (%) 
Mean CV Control (%) % aggr CV Control (%) 
Donor 2 
10% FCS 6520 (11.0) 
0.5% BSA 1489 (18.0) 
Bovine pancreas insulin (100 ng/ml) 3344 (9.9) 
Bovine pancreas insulin (100 ng/ml) 
+hr-IGF-1 (100 ng/ml) 3186 (11.0) 
Insulin-transferrin-sodium-selenite 
complex (5 pg/ml) 3191 (14.0) 
100 36.4 (2.3) 100 
23 17.5 (9.0) 48 
51 21.1 (5.1) 58 
49 20.5 (8.6) 56 
49 20.8 (4.8) 57 
Percentage of control = 10% FCS 
FCS, fetal calf serum; BSA, bovine serum albumin. 
Donor numbers refer to Table I. 
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biglycan, f ibromodulin, type XI col lagen and other 
physiological ly impor tant  but less abundant  extra- 
cel lular macromolecules were not studied with 
these approaches. 
Both IGF-1 and IGF-2, and insulin, part ly  restored 
35S incorporat ion levels of human cart i lage cells 
cultured in agarose. These findings were in 
agreement with the results obtained by others for 
monolayer-cultured rabbit chondrocytes [6] or for 
t issue-cultured cart i lage [8, 9, 16, 28]. However, in 
our series, 3sS incorporat ion in serum-free con- 
ditions hardly amounted to 50% of the basal  (FCS) 
values. 
The extracel lu lar  matr ix  may contain factors that  
are required for an opt imal activity of both IGF and 
insulin. Amongst these factors, TGF-fl is expressed 
in vitro by isolated chondrocytes [13] or by the same 
cells in t issue cul ture [29]. When these cells are 
surrounded by an extracel lu lar  matrix, the factors 
will be stored in their  immediate environment.  
Therefore,  metabol ic responses of chondrocytes in 
artif icial matr ices may thus differ from that  of 
chondrocytes mainta ined in the or iginal  extracel lu- 
lar environment.  
The st ructura l  homology between both IGFs and 
insul in is 50-70% [30]. They b ind- -w i th  different 
af f in i t ies- - to thei r  mutual  receptors  and elicit 
the same biological responses [4]. The combinat ion 
of insul in and IGF-1 is not a priori expected to 
exert  additive or synergist ic effects on aggrecan 
Table VIII 
SO¢ incorporation in aggrecans: effects of transforming rowth 
factor as a single mediator or in combination with bovine pancreas 
insulin on the proportion of aggrecan aggregates produced by 
chondrocytes in suspension culture 
Aggrecan 
aggregate (%) CV Control (%) 
Donor 8 
10% FCS 27.6 (4.8) 100 
0.5% BSA 19.2 (9.7) 70 
Bovine pancreas insulin 
(100 ng/ml) 18.9 (7.4) 68 
Bovine pancreas insulin 
(100 ng/ml) + TGF-fl 
0.5 ng/ml 20.2 (5.4) 73 
1 ng/ml 21.3 (10.2) 77 
10 ng/ml 21.1 (5.5) 76 
Percentage ofcontrol situation =10% FCS. 
FCS, fetal calf serum; BSA, bovine serum albumin. 
Donor numbers refer to Table I. 
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Table IX 
S04 incorporation in aggrecans: effects of human serum transferrin alone or in combination with bovine 
pancreas insulin on 3~S incorporation in aggrecan by chondrocytes in suspension culture 
pg/1 × 10 ~ cells/h 
Donor 4 Donor 9 
Mean CV Control (%) Mean CV Control(%) 
10% FCS 
O.5% BSA 
Bovine pancreas insulin 
(100 ng/ml) 
hs-transferrin 
0.1 #g/ml 
1.0/~g/ml 
10.0 pg/ml 
20.0 tt g/ml 
Bovine pancreas insulin 
(100 ng/ml) + hs-transferrin 
1 gg/ml 
10 #g/ml 
100 pg/ml 
10 000 pg/ml 
7345 (10) 100 2350 (9) 100 
2025 (11) 27 329 (3) 14 
- -  705 (3) 30 
2336 (13) 32 - -  - -  - -  
2103 (9) 33 - -  - -  - -  
2189 (6) 34 - -  - -  - -  
2372 (10) 32 - -  - -  - -  
682 (1) 29 
588 (3) 25 
587 (3) 25 
635 (4) 27 
FCS, fetal calf serum; BSA, bovine serum albumin; hs, human serum. 
Donor numbers refer to Table I. 
synthesis. Lack of synergy may also be explained by 
the capability of insulin to downregulate type 1 
IGF-receptors on connective tissue cells [31]. 
Because insulin is capable of upregulating the 
translocation of cycling type 2 receptors to the 
plasma membrane of some cell types [32], synergic 
effects, if any, between IGF-2 and insulin with 
respect to aggrecan synthesis in this system remains 
to be investigated. 
TGF-fl, as a single growth factor in the incubation 
media, had an inconstant effect on 35S-incorporation 
in proteoglycan by the chondrocytes in agarose. 
Inconstant effects to TGF on chondrocyte proteo- 
glycan synthesis, were previously reported. TGF-fl 
increased proteoglycan synthesis in cartilage tissue 
in vitro [15, 18] but downregulated aggrecan by the 
same cells in agarose [33]. However, in the same 
culture condition TGF-fl completely maintained 
aggrecan synthesis--as quantified b~-35S-incorpor - 
at ion-- in an insulin-supplemented, serum-free 
incubation medium. The additive effects of TGF-fi 
and bovine pancreas insulin may reflect different 
post-receptor mechanisms. Another possible expla- 
nation is the mutual induction of their mutual 
receptors, or of some growth factor binding and 
activating proteins as described for the IGFs 
[2, 34, 35]. 
The fact that TGF-f l - -and the IGF's as single 
factors -had less effect on cartilage cells depleted 
from their original environment, and the inconsist- 
ent effect of TGF-fl on these cells i l lustrate the 
contribution of factors other than insulin, e.g. 
plasma membrane receptors, post-receptor mechan- 
isms and various binding (activating) proteins, in 
the response to TGF. The contribution of these 
factors may be highly variable depending on the 
batch of chondrocytes. 
Proteoglycan metabolism in serum-free culture 
resulted in a decreased proportion of aggregate 
forming aggrecans. Supplementing the culture 
media with IGF, insulin or TGF-fi partly restored the 
ability of the cells to produce the aggregate-forming 
aggrecan. Reports on the effects of both IGF and 
TGF-fl on the nature of the proteoglycan synthesized 
in vitro are somewhat conflicting. IGF did not alter 
the hydrodynamic size of the aggrecan produced by 
tissue-cultured bovine chondrocytes in serum-free 
media [8], though it was shown to inhibit the 
degradation of aggrecan in IL-l-treated tissue- 
cultured pig cartilage [29]. TGF-fl did not alter the 
nature of the aggrecan produced by tissue-cultured 
dog chondrocytes in serum-free media [16], though 
it decreased the loss of proteoglycan from bovine 
cartilage cultured in serum-free conditions [15]. 
Although our results may suggest that the 
replacement of serum by selected growth factors 
do6s not compensate for the serum protease 
inhibitors, further experiments will be needed to 
clarify these discrepancies. 
Human serum transferrin, though generally 
accepted to be an indispensable supplement where 
the regulation of proliferation is concerned, did not 
affect the synthesis of proteoglycan. 
In summary, proteoglycan synthesis, as measured 
by 3~S incorporation by isolated art icular cartilage 
cells in suspension culture, seems to largely depend 
on the presence of a combination of selected growth 
and differentiation factors, e.g. TGF-fl, insulin 
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and/or  IGF, the i r  receptors  and an adequate  
funct ion of the i r  respect ive post - receptor  mechan-  
isms. More invest igat ions are mandatory  to 
apprec iate the effects of these exogenous 
supplements  on proteoglycan catabol ism. 
Acknowledgments  
This work was suppor ted  by European Economic  
C0mmuni ty - -Br idge  grant  BIOT-0196 and Nat ion-  
aal Fonds voor  Wetenschappel i jk  Onderzoek,  
Belgium grants  3.0077.99 and 9.850588. A.-M. 
Mal fa i t  is an NFWO research assistant.  
References 
1. Barnes D, Sato G. Serum-free cell culture: a unifying 
approach. Cell 1980;22:649-55. 
2. Baxter RC, Martin JL. Binding proteins for 
insulin-like growth factors in adult rat serum. 
Comparison with other human and rat binding 
proteins. Biochem Biophys Res Commun 
1987;147:408-15. 
3. Straus DS. Growth-stimulatory actions of insulin 
in vitro and in vivo. Endocrine Rev 1984;5:356-69. 
4. Rechler MM, Nissley SP The nature and regulation 
of the receptors for insulin-like growth factors. Ann 
Rev Physiol 1985;47:425-42. 
5. Webber RJ, Zitaglio T, Hough AJ, Jr. Serum-free 
culture of rabbit meniscal fibrochondrocytes: 
proliferative response. J Orthop Res 1988;6:13-24. 
6. Guenther HL, Guenther HE, Froesch ER, Fleisch H. 
Effect of insulin-like growth factor on collagen 
and glycosaminoglycan synthesis by rabbit articular 
chondrocytes in culture. Experientia 1982;38:979-81. 
7. Dukovich M, Severin JM, White SJ, Yamazaki S, 
Mizel SB. Stimulation of fibroblast proliferation 
and prostaglandin production by purified recombi- 
nant murine interleukin-1. Clin Immunol Immuno- 
pathol 1986;38:381-9. 
8. McQuillan DJ, Handley CJ, Campbell MA, Bolis S, 
Milway VE, Herington AC. Stimulation of proteo- 
glycan biosynthesis by serum and insulin-like 
growth factor-I in cultured bovine articular 
cartilage. Biochem J 1986;240:423-30. 
9. Luyten FP, Hascall VC, Nissley SP, Morales TI, Reddi 
H. Insulin-like growth factors maintain steady-state 
metabolism of proteoglycans in bovine articular 
cartilage explants. Arch Biochem Biophys 
1988;267:416-25. 
10. Demarquay D, Dumortier MF, Tsagris L, Bour- 
guignon J, Nataf V, Corvol MT. In vitro insulin-like 
growth factor I interaction with cartilage cells 
derived from postnatal animals. Horm Res 
1990;33:111-15. 
11. Mohan S, Jennings JC, Linkhart TA, Baytink DJ. 
Primary structure of human skeletal growth factor: 
homology with human insulin-like growth factor-II. 
Biochim Biophys Acta 1988;966:44-55. 
12. Scheven BA, Hamilton NJ. Longitudinal bone growth 
in vitro: effects of insulin-like growth factor I on 
growth hormone. Acta Endocrinol Copenh 
1991;124:602-7. 
13. Ellingsworth LR, Brennan JE, Fok K et al. Antibodies 
to the N-terminal portion of cartilage-inducing 
factor-A and transforming rowth factor. J Biol 
Chem 1986;261:12 362-7. 
14. Seyedin SM, Thompson AY, Bentz H et al. Cartilage-in- 
ducing factor-A: apparent identity to transforming 
growth factor-beta. J Biol Chem 1986;261:5693-5. 
15. Morales TI, Roberts AB. Transforming rowth factor 
beta regulates the metabolism of proteoglycans in
bovine cartilage organ cultures. J Biol Chem 
1988;263:12 828-31. 
16. Burton-Wurster N, Lust G. Fibronectin and proteogly- 
can synthesis in long-term cultures of cartilage 
explants in Ham's F12 supplemented with insulin 
and calcium: effects of the addition of TGF-beta. 
Arch Biochem Biophys 1990;283:27-33. 
17. Vivien D, Galera P, Loyau G, Pujol JP. Differential 
response of cultured rabbit articular chondrocytes 
(RAC) to transforming rowth factor beta (TGF- 
beta)--evidence for a role of serum factors. Europ J 
Cell Biol 1991;54:217-23. 
18. Pujol JP, Galera P, Redini F, Mauviel A, Loyau G. Role 
of cytokines in osteoarthritis: comparative effects of 
interleukin 1 and transforming rowth factor-beta 
on cultured rabbit articular chondrocytes. J 
Rheumatol 1991;18(Suppl. 27):75-6. 
19. Chandrasekhar S, Harvey AK. Transforming rowth 
factor-beta is a potent inhibitor of IL-1 induced 
protease activity and cartilage proteoglycan degra- 
dation. Biochern Biophys Res Commun 
1988;157:1352-9. 
20. Andrews HJ, Edwards TA, Cawston TE, Hazleman 
BL. Transforming growth factor-beta causes part ial  
inhibition of interleukin 1-stimulated cartilage 
degradation i vitro. Biochem Biophys Res Commun 
1989;162:144-50. 
21. Elford PR, Lamberts SWJ. Contrasting modulation by 
transforming rowth factor-beta-1 of insulin-like 
growth factor-I production in osteoblasts and 
chondrocytes. Endocrinology 1990;127:1635-9. 
22. Green WT, Jr. Behavior of articular chondrocytes in
cell culture. Clin Orthop Rel Res 1971;75:248-60. 
23. Kuettner KE, Pauli BU, Gall G, Memoli VE, Schenk 
RK. Synthesis of cartilage matrix by mammalian 
chondrocytes in vitro. I. Isolation, culture 
characteristics and morphology. J Cell Biol 
1982;93:743-50. 
24. Benya PD, Schaffer JD. Dedifferentiated chondro- 
cytes reexpress the differentiated collagen pheno- 
type when cultured in agarose gels. Cell 
1982;30:215-24. 
25. Verbruggen G, Veys EM, Wieme N et al. The synthesis 
and immobilisation of cartilage specific proteo- 
glycan by human chondrocytes in different con- 
centrations of agarose. Clin Exp Rheum 
1990;8:371-8. 
26. Cornelissen M, Verbruggen G, Malfait AM~ Veys EM, 
Broddelez C, De Ridder L. The study of representa- 
tive populations of native aggrecan aggregates 
synthesized by human chondrocytes in vitro. J Tiss 
Cult Meth 1993;15:139-46. 
27. Pearson JP, Mason RM. The stability of bovine nasal 
proteoglycans during isolation and storage. 
Biochim Biophys Acta 1977;498:176-88. 
28. Tyler JA. Insulin-like growth factor 1 can decrease 
degradation and promote synthesis of proteoglycan 
in cartilage exposed to cytokines. Biochem J 
i989;260:543-8. 
Osteoarthritis and Cartilage Vol. 3 No. 4 259 
29. Young MF, Robey PG, Reddi AH, Roberts AB, Sporn 
MB, Termine JD. TGF-beta expression in fetal 
bovine boiie-forming cells. J Bone Min Res 
1986;l(Suppl. 1):155. 
30. Zapf J, Froesch ER, Humbel RE. The insulin-like 
growth factors (IGF) of human serum: chemical and 
biological characterization and aspects of their 
possible physiological role. Curr Top Cell Reg 
1981;19:257-309. 
31. Rosenfeld RG, Dollar LA. Characterization of the 
somatomedin-C/insulin-like growth factor (SM-C/ 
IGF-I) receptor on cultured human fibroblast 
monolayers: regulation of receptor concentrations 
by SM-C/IGF-I and insulin. J Clin Endocrinol Metab 
1982;55:434-40. 
32. Wardezala LJ, Simpson IA, Rechler MM, Cushman 
SW. Potential mechanism of the stimulatory action 
of insulin on insulin-like growth factor II binding to 
the isolated rat adipose cell: apparent redistribu- 
tion of receptors recycling between a large 
intracellular pool and the plasma membrane. JBiol  
Chem 1984;259:8378-83. 
33. Skantze KA, Brinckerhoff CE, Colliier JP. Use of 
agarose culture to measure the effect of transform- 
ing growth factor beta and epidermal growth factor 
on rabbit articular chondrocytes. Cancer Res 
1985;45:4416-21. 
34. Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke 
MB, Bierich JR. Insulin-like growth factor I 
(IGF-I)-binding protein complex is a better mitogen 
than free IGF-I. Endocrinology 1989;125:766-72. 
35. Conover CA. A unique receptor-independent mechan- 
ism by which insulin-like growth factor I regulates 
the availability of insulin-like growth factor binding 
proteins in normal and transformed human 
fibroblasts. J Clin Invest 1991;88:1354-61. 
